Skip to main content
Mydecine Innovations Group Inc. logo

Mydecine Innovations Group Inc. — Investor Relations & Filings

Ticker · MYCO LEI · 254900C6LWGCB35YSK30 CSE Professional, scientific and technical activities
Open in API
Filings indexed 413 across all filing types
Latest filing 2025-07-10 Regulatory Filings
Country CA Canada
Listing CSE MYCO

About Mydecine Innovations Group Inc.

https://www.mydecine.com/

Mydecine Innovations Group Inc. is a biotechnology and life sciences company focused on the research, development, and commercialization of innovative first- and second-generation novel therapeutics. The company is dedicated to addressing mental health conditions and addiction, particularly target indications with high mortality rates that have historically lacked innovation. Mydecine utilizes nature-sourced compounds, such as psilocybin, in its pipeline development. Key therapeutic areas include Post-Traumatic Stress Disorder (PTSD) and nicotine addiction. The company's pipeline includes specific drug candidates such as MYCO-005, MYCO-006, and MYCO-007.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Venture Issuer Basic Certificate” certifying the interim financial report and MD&A for the quarter ended March 31, 2025. It is not the interim report or MD&A itself, nor an earnings release or audit report. It is a regulatory certificate filing under Canadian NI 52-109 and does not fit any other specific category, so it falls into the fallback “Regulatory Filings” category.
2025-07-10 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a NI 52-109 Form 52-109FV2 certification by the CFO attesting to interim financial statements and interim MD&A. It is not the interim report itself (IR), nor an announcement of publication (RPA), nor any other substantive report type. It is a regulatory certificate filing. Therefore it falls under the fallback category “Regulatory Filings” (RNS).
2025-07-10 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024” prepared under Form 51-102F1, and provides management’s detailed discussion of interim results, operations, liquidity, and outlook. This is a standalone MD&A section for a quarterly period, matching the definition of Management Reports (Code: MDA).
2025-07-10 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for the period ended March 31, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Income/Loss, Statement of Shareholders' Deficiency, and Statement of Cash Flows) along with detailed notes to the financial statements. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. Q1 2025
2025-07-10 English
News release - English.pdf
Report Publication Announcement Classification · 1% confidence The document is a short press release (≈4,800 characters) providing an update on the timing of the company’s annual financial statements and interim filings, not the filings themselves. It does not include detailed financials but states when the Annual Filings and Interim Filings will be published. Under the “menu vs meal” rule, announcements about the timing or publication of reports are classified as Report Publication Announcements (RPA).
2025-06-26 English
Material change report - English.pdf
Regulatory Filings Classification · 1% confidence The document is the prescribed Canadian securities form (“Form 45-106F1 Report of Exempt Distribution”) filed on SEDAR+ to comply with National Instrument 45-106 prospectus exemption rules. It provides detailed items about issuer, distribution dates, purchasers, exemptions, compensation, etc. This is a specialized regulatory filing rather than an annual or interim report, earnings release, management change notice, or other more specific category. Therefore it falls into the general Regulatory Filings category (RNS).
2025-05-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.